Eur Radiol:肝癌累及了肝静脉或下腔静脉,经动脉化疗栓塞后总生存率怎么样?

2021-01-05 shaosai MedSci原创

肝癌累及了肝静脉或下腔静脉,经动脉化疗栓塞后总生存率怎么样?

目的:目前尚未建立有效的治疗侵袭肝静脉(HV)或下腔静脉(IVC)的肝细胞癌(HCC)的治疗方法。本研究旨在确定经肝动脉化疗栓塞(TACE)对HV或IVC侵袭的HCC患者的治疗效果,并建立风险预测模型。

方法:回顾性分析1997年至2019年间接受TACE作为肝癌侵袭HV或IVC的一线治疗的患者的数据。

结果:本研究共纳入296位患者的数据(1997-2006年的数据组成培训队列,n = 174; 2007-2019年的数据组成验证队列,n = 122)。TACE术后患者的生存期中位数为7.3个月,在34.1%的患者中达到了客观预计效果。训练队列的多变量Cox分析确定了五个预处理因素(最大肿瘤尺寸> 10 cm、浸润性HCC、合并门静脉浸润、肝外转移以及ECOG表现状态1),这些因素可用于创建总生存率的预测模型。低风险组(风险总和:0-3)和高风险组(风险总和:4-7)在验证队列中的总生存时间中位数分别为14和4.2个月(p <0.001)。应用于验证队列的总生存率预测模型的时间依赖性ROC曲线显示出可接受的AUC值(6个月和1年时分别为0.723和0.667)。

结论:TACE对于部分侵犯HV或IVC的肝癌患者有效。本预测模型有助于筛选出适用TACE术对治疗的患者。

原始出处:

Hee Ho Chu,Seng-Yong Chun,Jin Hyoung Kim,et al. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. PMID:33241523DOI:10.1007/s00330-020-07536-8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991368, encodeId=4c4e199136833, content=<a href='/topic/show?id=c2602022133' target=_blank style='color:#2F92EE;'>#下腔静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20221, encryptionId=c2602022133, topicName=下腔静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Sun Mar 14 14:43:44 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984602, encodeId=ec64198460272, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Dec 18 07:43:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698183, encodeId=889e169818325, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 11 23:43:44 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256802, encodeId=82aa125680282, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Jan 07 01:43:44 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914208, encodeId=00d191420899, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 22:03:53 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040335, encodeId=f3e11040335ea, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Jan 05 13:43:44 CST 2021, time=2021-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991368, encodeId=4c4e199136833, content=<a href='/topic/show?id=c2602022133' target=_blank style='color:#2F92EE;'>#下腔静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20221, encryptionId=c2602022133, topicName=下腔静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Sun Mar 14 14:43:44 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984602, encodeId=ec64198460272, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Dec 18 07:43:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698183, encodeId=889e169818325, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 11 23:43:44 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256802, encodeId=82aa125680282, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Jan 07 01:43:44 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914208, encodeId=00d191420899, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 22:03:53 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040335, encodeId=f3e11040335ea, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Jan 05 13:43:44 CST 2021, time=2021-01-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991368, encodeId=4c4e199136833, content=<a href='/topic/show?id=c2602022133' target=_blank style='color:#2F92EE;'>#下腔静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20221, encryptionId=c2602022133, topicName=下腔静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Sun Mar 14 14:43:44 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984602, encodeId=ec64198460272, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Dec 18 07:43:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698183, encodeId=889e169818325, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 11 23:43:44 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256802, encodeId=82aa125680282, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Jan 07 01:43:44 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914208, encodeId=00d191420899, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 22:03:53 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040335, encodeId=f3e11040335ea, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Jan 05 13:43:44 CST 2021, time=2021-01-05, status=1, ipAttribution=)]
    2021-06-11 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991368, encodeId=4c4e199136833, content=<a href='/topic/show?id=c2602022133' target=_blank style='color:#2F92EE;'>#下腔静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20221, encryptionId=c2602022133, topicName=下腔静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Sun Mar 14 14:43:44 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984602, encodeId=ec64198460272, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Dec 18 07:43:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698183, encodeId=889e169818325, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 11 23:43:44 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256802, encodeId=82aa125680282, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Jan 07 01:43:44 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914208, encodeId=00d191420899, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 22:03:53 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040335, encodeId=f3e11040335ea, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Jan 05 13:43:44 CST 2021, time=2021-01-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1991368, encodeId=4c4e199136833, content=<a href='/topic/show?id=c2602022133' target=_blank style='color:#2F92EE;'>#下腔静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20221, encryptionId=c2602022133, topicName=下腔静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Sun Mar 14 14:43:44 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984602, encodeId=ec64198460272, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Dec 18 07:43:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698183, encodeId=889e169818325, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 11 23:43:44 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256802, encodeId=82aa125680282, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Jan 07 01:43:44 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914208, encodeId=00d191420899, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 22:03:53 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040335, encodeId=f3e11040335ea, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Jan 05 13:43:44 CST 2021, time=2021-01-05, status=1, ipAttribution=)]
    2021-01-06 Houqiangcn

    好好学习天天向上

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1991368, encodeId=4c4e199136833, content=<a href='/topic/show?id=c2602022133' target=_blank style='color:#2F92EE;'>#下腔静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20221, encryptionId=c2602022133, topicName=下腔静脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=295c372, createdName=chaojitidian, createdTime=Sun Mar 14 14:43:44 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984602, encodeId=ec64198460272, content=<a href='/topic/show?id=40d93356656' target=_blank style='color:#2F92EE;'>#化疗栓塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33566, encryptionId=40d93356656, topicName=化疗栓塞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/4v5DMqK7WnzoBdibNsryQ8OEM5gFSdRH9j3HNCKPfKXlObInweOSHdQPATeTicYp7nvg3bsgicjLgRkdlhrpry21w/132, createdBy=6bf82500013, createdName=ms5822920152752585, createdTime=Sat Dec 18 07:43:44 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698183, encodeId=889e169818325, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Fri Jun 11 23:43:44 CST 2021, time=2021-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256802, encodeId=82aa125680282, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Jan 07 01:43:44 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914208, encodeId=00d191420899, content=好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d014978118, createdName=Houqiangcn, createdTime=Wed Jan 06 22:03:53 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040335, encodeId=f3e11040335ea, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Jan 05 13:43:44 CST 2021, time=2021-01-05, status=1, ipAttribution=)]
    2021-01-05 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

J Gastroenterology:直接作用抗病毒药可改善肝细胞癌治疗后的生存率和复发率

全球估计有180万人受到丙型肝炎病毒(HCV)感染的影响,同时丙肝也是肝细胞癌(HCC)的主要原因。

Sirtex Medical和China Grand Pharmaceutical宣布SIR-Spheres Y-90树脂微球获得NMPA认可

SIR-Spheres®Y-90树脂微球的新药申请(NDA)已获得中国NMPA的批准。

Signal Transduct Target Ther:浙大蔡秀军团队揭示外泌体介导的肝癌靶向耐药细胞间传播新机制

肝细胞癌(HCC)是最常见的原发性肝癌,在全球范围内,其发病率位于恶性肿瘤的第六位,其病死率在肿瘤相关死亡原因中的排名第四。对于晚期肝癌,索拉非尼是首个获得FDA批准的靶向治疗肝细胞肝癌的药物。

Science:最“安全”基因治疗载体似乎并不安全,血友病患者接受治疗后患上肝癌

荷兰生物制药公司uniQure的一项针对B型血友病的基因疗法被美国FDA叫停,起因是接受治疗后该患者患上了肝细胞癌。

CELL: 复旦大学樊嘉团队揭示早期复发肝癌的单细胞景观

我们对于与肝癌术后快速复发相关的分子机制仍知之甚少。对肿瘤复发的深入探索可以提高我们对肿瘤发生和进展相关机制的理解,有助于发现更有效的HCC治疗策略,包括免疫疗法。

TAG: 辅助性经导管动脉化疗栓塞术在肝癌肝切除患者中的有效性分析

肝细胞癌(HCC)是全球癌症相关死亡率的第四大最常见原因。手术切除,肝移植和肿瘤消融是用于治疗HCC的三种治疗方法。